
    
      This is an open-label single-arm Phase II trial for patients with metastatic pancreatic
      cancer who have failed first line Gemcitabine-based therapy. Patients will be treated with a
      combination of Capecitabine and Lapatinib, a dual tyrosine-kinase inhibitor of EGFR and
      HER-2.
    
  